Company Profile
Nippon Chemiphar provides the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and globally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels
57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development.
Its portfolio also includes NC-2500, a XOR inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development, and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development. Additionally, it develops NC-2700, a URAT1 inhibitor for hyperuricemia, guot currently under preclinical development.
Its portfolio also includes NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety currently under Phase 1 development, DFP-17729, a cancer microenvironment improving agent far pancreatic cancer currently under phase 2 development, and DE-P-14323, an anti-cancer agent for non-small cell lung cancer currently under phase 2 development.
It also is involved in the development of Soleton, an analgesic and anti-inflammatory drug; and Calvan, a blocker for huntington's disease currently under phase 2 development Quasi-drugs, nutrients, health foods, cosmetics, and various types of creams. Incorporated in 1950 and headquartered in Tokyo, Japan, Nippon Chemiphar was formerly known as Hitachi Chemical Co., Ltd. before rebranding in 1970.